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“Nothing in life is to be feared, it is only to be understood.  
Now is the time to understand more, so that we may fear less.” 





“Even miracles take a little time.” 





“You have brains in your head. You have feet in your shoes.  
You can steer yourself any direction you choose.  
You're on your own. And you know what you know. 
And you are the one who'll decide where to go...” 
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The primary cause of cardiovascular disease is atherosclerosis, which is an inflammatory 
disease resulting in plaque formation within blood vessels. Myeloperoxidase (MPO), an 
enzyme released by activated leukocytes in atherosclerosis catalyses the formation of 
hypochlorous acid (HOCl) which reacts readily with nucleic acids forming chlorinated 
nucleosides. There is increasing evidence that the formation of these chlorinated 
adducts has adverse effects, and elevated levels of these species are present in different 
inflammatory contexts, including atherosclerotic lesions.  
The focus of Chapters 3 and 4 in this Thesis was to examine the effects of chlorinated 
nucleosides on endothelial cells (HCAEC) and smooth muscle cells (HCASMC) isolated 
from the human coronary artery. Studies in HCAEC and HCASMC showed that each of 
the chlorinated nucleosides studied incorporated into the RNA and DNA of these cells. 
However, only 8-chloroadenosine (8ClA) was shown to influence the metabolic activity 
and cell viability in HCAEC. 8ClA was converted to 8-ClATP, which was associated with 
alterations in the ability of HCAEC to perform glycolysis. Exposure of HCAEC to 8ClA also 
induced endoplasmic reticulum (ER) stress, resulting in apoptotic cell death and 
activation of the Nrf2 antioxidant stress response.  
In Chapter 4, studies in HCASMC demonstrated that 8ClA and 5-chloro-2’-deoxycytidine 
(5CldC) decreased both the metabolic activity and proliferation of HCASMC. The effects 
of 8ClA on HCASMC were similar to those observed in HCAEC though less profound as 
the viability of HCASMC was unaffected, though some ER stress was apparent. In 
contrast, exposure of HCASMC to 5CldC resulted in alterations to pro-inflammatory 
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signalling, a large increase in the expression of MMP2 and MMP9 and phenotypic 
changes.   
A potential source of chlorinated nucleosides under inflammatory conditions was 
explored in Chapter 5. The differentiation of PLB-985 cells into neutrophils was 
optimised, together with various treatment conditions to induce the productions 
neutrophil extracellular traps (NETs). The concentrations of modified nucleosides in 
both NET DNA and nuclear DNA of these cells was quantified using LC-MS/MS and it was 
shown that phorbol myristate acetate (PMA) and HOCl treatment gave 8-oxo-7,8-
dihydro-deoxyguanosine (8oxodG) and 5CldC, respectively, in both NET and nuclear 
DNA. 
Overall, the studies outlined in this Thesis provide insight into a potential new source of 
modified nucleosides in disease. These data show that chlorinated nucleosides are not 
only biomarkers of disease but can alter cellular function in both HCAEC and HCASMC. 
Therefore, these chlorinated adducts could play a role in the development and 
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